Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

NCT07332507 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

NIH

Sponsor class

Conditions

Recurrent Plasmablastic Lymphoma
Refractory Plasmablastic Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Positron Emission Tomography
DRUG: Teclistamab

Sponsor

National Cancer Institute (NCI)